Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG-PRIME: BCG Vaccination to Prevent COVID-19 and Respiratory Infections in Elderly
NCT04537663Phase 4Completed
- Start
- Sep 2020
- Primary completion
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and respiratory tract infection (RTI) comparing BCG Vaccine Arm with Placebo Arm (2 arms). Primary endpoint: COVID-19 or clinically relevant respiratory tract infection at 180 days. Started Sep 2020; status: completed.
02
Drugs
bcg vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT04537663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537663.